Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Anebulo Pharmaceuticals, Inc. (ANEB), a micro-cap pharmaceutical company with a market capitalization of $40.26 million and current share price of $0.95, has regained compliance with Nasdaq’s listing rules following the approval of the removal of certain restrictions on its common stock, the company disclosed on Monday. The pharmaceutical company, which specializes in preparations and is headquartered in Lakeway, Texas, received a letter from The Nasdaq Stock Market LLC on April 11, 2025, confirming the regained compliance.
The compliance issue stemmed from voting and transfer restrictions associated with shares issued during a private placement in December 2024. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 17.52 and holds more cash than debt on its balance sheet. Anebulo’s stockholders voted to remove these restrictions, as reported in a Current Report on Form 8-K filed on April 7, 2025. Following this action, Nasdaq reviewed the matter and determined that Anebulo Pharmaceuticals met the requirements of Nasdaq Listing Rule 5635(b), which pertains to shareholder approval for certain equity compensation and other equity-related transactions.
The resolution of this compliance matter closes the chapter on Anebulo’s recent regulatory challenges with the stock exchange. The company, which is incorporated in Delaware and reports its fiscal year-end on June 30, trades under the ticker symbol ANEB on The Nasdaq Stock Market LLC.
This development is based on the company’s latest filing with the Securities and Exchange Commission and marks an important step for Anebulo as it continues its operations within the regulatory framework of the public market. The company’s business address is c/o Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, 78734, and it can be contacted via phone at (512) 598-0931.
Investors and stakeholders in Anebulo Pharmaceuticals may view this news as a positive indication of the company’s ability to navigate compliance requirements and maintain its listing on a major stock exchange. The stock has experienced significant volatility this year, with a year-to-date decline of 43.45% and notably shows a negative correlation to broader market movements with a beta of -1.14. InvestingPro subscribers have access to over 10 additional key insights and real-time metrics to better evaluate ANEB’s investment potential.
In other recent news, Anebulo Pharmaceuticals reported a net loss of $2.5 million for the second quarter of fiscal year 2025, marking a slight improvement from the $2.7 million loss in the same period last year. The company also completed a $15 million equity private placement during the quarter, ending December 2025 with approximately $15 million in cash reserves. Analysts from Benchmark maintained a Speculative Buy rating on Anebulo stock with a price target of $8, reflecting continued support for the company’s strategic moves and financial performance. Additionally, Anebulo has amended its articles of incorporation to increase its authorized common stock from 50 million to 75 million shares, following shareholder approval. The company also restructured its Board of Directors to a declassified structure, allowing for annual elections of all directors. In response to a Nasdaq compliance issue, Anebulo entered a lock-up agreement with 22NW Fund, LP, to address a change in control resulting from a private placement. Anebulo has until April 10, 2025, to secure stockholder approval for lifting voting and transfer restrictions associated with this agreement. The company’s annual stockholders meeting is scheduled for April 4, 2025, with deadlines for stockholder proposals set for February 22, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.